Nativis Incorporated appoints new CSO

pharmafile | May 23, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Nativis 

Nativis, a clinical stage life science bio-clectronic company, has appointed Dr Kenneth Ferguson to the position of Chief Scientific Officer. The company is initially developing a non-invasive treatment for brain cancer that uses ultra-low radio frequency energy to regulate metabolic pathways on the molecular and genetic levels.

Dr Ferguson arrives at Nativis after having had spells as the Chief Development Officer Omeros Corporation, where he played a role in the development of all compounds. In particular, this meant that he aided in the process of Omidria being taken through to regulatory approval. Prior to this, he was CEO of VacTX – a healthcare startup that developed lipopeptide vaccines.

Commenting on his appointment, Dr Ferguson said: “Nativis is in a unique position with its novel, platform technology, and I am very excited to join the team at this pivotal time in the Company’s history. As the company successfully develops and optimizes its ulRFE technology for the treatment of glioblastoma multiforme, a very complex and difficult area to treat, the impact on patient care for diseases like cancer and other serious ailments could be monumental.”

Chris Rivera, Chief Executive Officer of Nativis, commented on the appointment: “We are very pleased to welcome Dr Kenneth Ferguson as Chief Scientific Officer to Nativis. Dr Ferguson is a well-recognized scientific leader in the biotech community and brings more than two decades of ground-up drug development experience to the organization and will play a vital role in our future scientific and clinical developments.”

Related Content

No items found

Latest content